Clinical TrialAug 5, 2026, 09:03 AM
SciSparc Subsidiary NeuroThera Launches Phase IIb Trial for Tourette Syndrome
AI Summary
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., has launched a Phase IIb clinical trial for its proprietary cannabinoid-based drug candidate, SCI-110, for the treatment of Tourette Syndrome in adults. The trial has initiated its U.S. site at the Yale Child Study Center, Yale School of Medicine, building on positive safety and efficacy results from a Phase IIa study that showed an average tic reduction of 21%. The study aims to evaluate the efficacy, safety, and tolerability of SCI-110, with additional sites in Germany and Israel.
Key Highlights
- SciSparc's subsidiary NeuroThera Labs launched a Phase IIb clinical trial for SCI-110.
- The trial is for the treatment of Tourette Syndrome (TS) in adults.
- The U.S. site for the trial is the Yale Child Study Center, Yale School of Medicine.
- SCI-110 is a proprietary cannabinoid-based drug candidate combining dronabinol with palmitoylethanolamide.
- Previous Phase IIa study showed an average tic reduction of 21% in participants.
- The Phase IIb trial is randomized, double-blind, placebo-controlled, and cross-over.
- Additional trial sites include Hannover Medical School (Germany) and Tel Aviv Sourasky Medical Center (Israel).
Price Impact
More from SPRC